MedTrace Logo

A 6-month, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of USPlus DERM to Promote Hair Growth in Men and Women With Self-perceived Thinning Hair.

NCT06920758 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-04-10

No results posted yet for this study

Summary

The goal of this clinical trial is to substantiate the effectiveness and safety of USPlus® DERM for self-perceived thinning hair compared to placebo in healthy men and women ages 25-65 over the course of six months of continued use. Participants will be asked to have attend three office visits, one phone call, have photos taken of their hair and answer questionnaires related to their thinning hair.

Conditions

  • Thinning Hair

Interventions

DIETARY_SUPPLEMENT

USPlus DERM Bioactive Fatty Acids 160 mg Softgels

USPlus® DERM Bioactive Fatty Acids (160 mg) Ingredient List (Per Softgel) Active: 100% Concentrated Lipidosterolic Extract of Saw Palmetto (Serenoa repens). Shell: Bovine Gelatin, Glycerin, Water

OTHER

Placebo softgel

Placebo Ingredient List: Palm oil Gelatin Glycerin Water Caramel color

Sponsors & Collaborators

  • U.S. Nutraceuticals, Inc. dba Valensa International

    collaborator UNKNOWN

  • Ablon Skin Institute Research Center

    lead OTHER

Principal Investigators

  • Glynis Ablon, MD, FAAD, PI · Ablon Skin Institute Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-16
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06920758 on ClinicalTrials.gov